Department of Cardiology, Renmin Hospital; School of Basic Medical Science, Wuhan University, Wuhan 430071, China; Institute of Model Animal of Wuhan University, Wuhan 430071, China.
Department of Cardiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Trends Mol Med. 2022 Jan;28(1):5-7. doi: 10.1016/j.molmed.2021.11.002. Epub 2021 Nov 26.
A recent paper published in Nature Medicine by Calle et al. reported anti-nonalcoholic steatohepatitis (NASH) efficiencies by acetyl-CoA carboxylase (ACC) 1/2 inhibitors alone or by co-administration with a ACC1/2 inhibitor and a diacylglycerol acyltransferase 2 (DGAT2) inhibitor. Whereas the monotherapy achieved remarkable reductions in liver steatosis but induced hyperlipidemia, DGAT2 inhibitor co-administration mitigated the increase in serum triglycerides (TGs).
最近，Calle 等人在《自然医学》杂志上发表的一篇论文报告了乙酰辅酶 A 羧化酶 (ACC) 1/2 抑制剂单独或与 ACC1/2 抑制剂和二酰基甘油酰基转移酶 2 (DGAT2) 抑制剂联合给药的抗非酒精性脂肪性肝炎 (NASH) 疗效。虽然单药治疗可显著减少肝脏脂肪变性，但会引起血脂异常，而 DGAT2 抑制剂联合给药可减轻血清甘油三酯 (TGs) 的增加。
